- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure，Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
- Interventions
- EHR-based Clinician Jumpstart
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–576
of 597
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- INOpulse®, Placebo, Long Term Follow Up
- Combination Product
- Lead sponsor
- Bellerophon
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
- Conditions
- Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis, Isolated Cutaneous Vasculitis, Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Urticarial Vasculitis, Vasculitis
- Interventions
- Not listed
- Lead sponsor
- Peter Merkel
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Epigallocatechin-3-gallate (EGCG)
- Drug
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 40 more
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Interventions
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Sarcoidosis
- Interventions
- Placebo, Golimumab, Ustekinumab
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 21 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- GB0139, Placebo
- Drug
- Lead sponsor
- Galecto Biotech AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Palm Springs, California + 29 more
- Conditions
- Interstitial Lung Disease
- Interventions
- Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- None (Observational Study)
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Denver, Colorado • Golden, Colorado + 18 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 765423, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Ocala, Florida + 11 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
- Interventions
- inhaled mosliciguat, Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- Pulmovant, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
- Conditions
- Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Simtuzumab, Simtuzumab placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
- Conditions
- Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
- Interventions
- Hyperpolarized 129Xe
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Interstitial Lung Disease
- Interventions
- alternative six minute walk test, Standard six minute walk test
- Procedure
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Interstitial Lung Diseases
- Interventions
- Hyperpolarized 129Xe
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GS-6624
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Stanford, California + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- AZD5055, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Pulmonary Fibrosis, Anxiety
- Interventions
- Digital cognitive behavioral therapy
- Device
- Lead sponsor
- Vicore Pharma AB
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- San Francisco, California • Salt Lake City, Utah
- Conditions
- Lung Diseases, Interstitial
- Interventions
- OFEV
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Chesterfield, Missouri • Kalispell, Montana + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Emphysema or COPD
- Interventions
- CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea
- Biological · Drug
- Lead sponsor
- Paul Szabolcs
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Vasculitis, Wegener's Granulomatosis
- Interventions
- Interleukin-10
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Interventions
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more